

# Incyte Biosciences UK LTD 's Carbon Reduction Plan

Supplier name

Incyte Biosciences UK Ltd

Publication date

March 2026

## Commitment to achieving net zero

### Commitment to Achieving Net Zero

Incyte Biosciences UK Ltd is committed to achieving Net Zero greenhouse gas emissions across UK operations by 2050, in line with UK Government policy and NHS supplier requirements.

As part of the global Incyte organisation, we align our UK strategy with the broader sustainability commitments of Incyte Corporation, including:

- Transition of the global leased fleet to hybrid and electric vehicles (EVs)
- Operational carbon neutrality ambitions
- Renewable electricity procurement across key sites
- Continuous environmental management improvements

We recognise the critical role of the healthcare sector in addressing climate change and are committed to supporting the NHS ambition to become the world's first net zero health system.

### Net Zero Target

Incyte Biosciences UK Ltd is separately committed to achieving Net Zero emissions across UK operations by 2050, in alignment with NHS and UK Government policy.

A formal science-based Net Zero transition plan will be developed and refined in line with relevant best practice guidance, including Science Based Targets initiative (SBTi) guidance where appropriate, and emerging UK and international standards.

## Baseline emissions footprint

Incyte Biosciences UK Ltd 's baseline year and current reporting year are the same for this publication (calendar year 2024).

### Baseline & current year: 2024

#### Additional details relating to the baseline emissions calculations:

Value provided for Scope 2 is market-based emissions

#### Baseline year emissions:

Emissions	Total (tCO <sub>2</sub> e)
Scope 1	2
Scope 2	13
Scope 3 (upstream transportation & distribution, waste generated in operations, business travel, employee commuting, downstream transportation & distribution)	143
<b>Total emissions</b>	<b>158</b>

## Emissions reduction targets

In order to continue our progress to achieving net zero, we prioritize the reduction of our operational greenhouse gas emissions wherever feasible.

In addition, our parent company, Incyte Corporation, has made commitments, including:

- **Fleet Electrification:** In July 2021, we committed to transition our global leased sales fleet to hybrid and electric vehicles (EVs). This project is ongoing, with approximately 50% of our fleet being hybrid or EV by January 1, 2025.
- **Operational carbon neutrality by the end of 2025:** We are focused on a combination of absolute emissions reductions and offsets to achieve this goal. We continue to reduce our scope 1 and 2 emissions through green building certifications, building improvements, renewable energy initiatives and converting our sales fleet to electric vehicles (EVs) and hybrids.

## Carbon reduction projects

### Completed carbon reduction initiatives

As part of the global Incyte organization, Incyte Biosciences UK Ltd has worked to reduce its scope 1 and 2 emissions, implementing measures such as partnering with our office landlord to source renewable electricity.

The following environmental management measures and projects have been completed or implemented by Incyte Corporation since 2021:

- **Renewable Electricity Procurement:** We strive to use renewable energy wherever possible. At our Switzerland-based European Headquarters and Yverdon BioPlant, we meet all our electricity needs through a combination of hydroelectric power and onsite solar installations. At our Wilmington (U.S.) campus, where we're unable to install a significant renewable energy source due to space constraints, we've purchased RECs since 2021 to match 100% of our electricity use with off-site renewable resources. To drive ongoing progress across our global footprint, we collaborate with local energy providers and landlords to integrate more renewable energy into our operations.
- **ISO certifications (Incyte's sole manufacturing facility):** Incyte's Yverdon BioPlant is certified to ISO 14001 (environmental management) and ISO 50001 (energy management), underscoring Incyte's commitment to continuous improvement in environmental performance.
- **Green building certifications:** We received Green Globes certification from the Green Building Initiative for two of the three buildings at our Global Headquarters (U.S.).
- **Waste Minimization and Diversion:** Incyte works to reduce our waste and manage it responsibly. We minimize raw material use in our operations and repurpose material where possible to avoid disposal. We prioritize landfill diversion practices for both non-hazardous and hazardous waste.

- **Fleet Electrification**

Transition to hybrid and electric vehicles across the global leased sales fleet

## **Future carbon reduction initiatives**

In the future Incyte hopes to implement further measures such as:

- Continuing our fleet electrification efforts
- Optimizing business travel
- Continued waste reduction and recycling initiatives

## **Governance and Accountability - Declaration and sign off**

This Carbon Reduction Plan has been completed in accordance with PPN 006 and associated guidance and reporting standard for Carbon Reduction Plans.

Emissions have been reported and recorded in accordance with the published reporting standard for Carbon Reduction Plans and the GHG Reporting Protocol corporate standard<sup>1</sup> and uses appropriate emission conversion factors for greenhouse gas reporting.

Scope 1 and Scope 2 emissions have been reported in accordance with the GHG Protocol, and the required subset of Scope 3 emissions have been reported in accordance with the published reporting standard for Carbon Reduction Plans and the Corporate Value Chain (Scope 3) Standard.<sup>2</sup>

This Carbon Reduction Plan has been reviewed and signed off by the board of directors.

### **Signed on behalf of the Incyte Biosciences UK Ltd:**

DocuSigned by:  
*Peter Williams*  
C25BE6B95D46496...

Name: Peter Williams

Title: General Manager UK&I

Date: 4 March 2026

Signed by:  
*Lee Heeson*  
3E18B376B00E472...

Name: Lee Heeson

Title: EVP, Incyte International

Date: 4 March 2026